Vista Finance LLC Has $339,000 Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Vista Finance LLC grew its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.9% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,113 shares of the company’s stock after purchasing an additional 72 shares during the period. Vista Finance LLC’s holdings in Medpace were worth $339,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Medpace by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company’s stock valued at $854,087,000 after purchasing an additional 25,704 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Medpace by 91.8% in the 4th quarter. Invesco Ltd. now owns 1,084,753 shares of the company’s stock valued at $360,387,000 after purchasing an additional 519,186 shares in the last quarter. Wasatch Advisors LP boosted its stake in shares of Medpace by 3.1% in the 4th quarter. Wasatch Advisors LP now owns 936,842 shares of the company’s stock valued at $311,247,000 after purchasing an additional 28,161 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Medpace by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 656,130 shares of the company’s stock valued at $218,031,000 after purchasing an additional 28,076 shares in the last quarter. Finally, Bessemer Group Inc. boosted its stake in shares of Medpace by 15.0% in the 4th quarter. Bessemer Group Inc. now owns 576,044 shares of the company’s stock valued at $191,379,000 after purchasing an additional 75,275 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Trading Down 1.9%

Shares of NASDAQ:MEDP opened at $298.25 on Friday. The stock has a market capitalization of $8.57 billion, a P/E ratio of 23.61, a P/E/G ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $459.77. The business has a 50-day moving average price of $298.85 and a two-hundred day moving average price of $322.77.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $3.06 by $0.61. The firm had revenue of $558.57 million during the quarter, compared to analysts’ expectations of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same period in the previous year, the business posted $3.20 EPS. As a group, equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MEDP. Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a research report on Monday, March 24th. Robert W. Baird reduced their price target on shares of Medpace from $340.00 to $313.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 23rd. Mizuho reduced their price target on shares of Medpace from $400.00 to $355.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 9th. Leerink Partners began coverage on shares of Medpace in a research report on Monday, March 24th. They set a “market perform” rating and a $330.00 price target on the stock. Finally, Truist Financial reduced their price target on shares of Medpace from $333.00 to $300.00 and set a “hold” rating on the stock in a research report on Wednesday, April 23rd. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $349.30.

Insider Activity

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the company’s stock in a transaction dated Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the sale, the director now directly owns 2,998 shares of the company’s stock, valued at $904,856.36. This represents a 36.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 20.30% of the stock is currently owned by company insiders.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.